Aarti Pharmalabs Limited Holds 7th AGM on Sep 22, 2026, Presents Investor Update
Aarti Pharmalabs Limited held its 7th AGM on Sep 22, 2026, presenting its investor update. For FY26, standalone revenue was ₹1,798 crore and consolidated revenue was ₹18,194 crore. The company is investing ₹400 crore in the Atali Greenfield project and ₹210 crore in Tarapur Brownfield expansion. It targets 15-18% revenue and EBITDA CAGR over the next 3-4 years.
The announcement provides an update on the company's strategic direction, significant investments in capacity expansion, and future growth targets. The AGM presentation offers insights into financial performance and operational highlights, which are material for investors.
The announcement details the company's AGM and investor presentation, including financial results and future plans. While the presentation highlights strengths and investments, the reported PAT figures for FY26 show a decline compared to FY25, and consolidated results are noted as not comparable. The overall tone is informative rather than strongly positive or negative.
Aarti Pharmalabs Limited held its 7th Annual General Meeting (AGM) on Tuesday, September 22, 2026. During the meeting, the company presented an investor presentation detailing its performance and strategic initiatives.
The presentation highlighted Aarti Pharmalabs' position as a leading small molecule CDMO/CMO company in India, with a strong focus on regulatory operations and expertise in novel chemistries. It is also the largest manufacturer of Xanthine Derivatives in India.
Financially, for FY26, the company reported standalone operational revenue of ₹1,798 crore and EBITDA margins of 22.6%, with a Profit After Tax (PAT) of ₹176 crore. Consolidated operational revenue for FY26 stood at ₹18,194 crore, with EBITDA margins at 22.12% and PAT at ₹1,747 crore. The company noted that consolidated accounts for the current period are not comparable with previous periods due to the entity becoming a joint venture with Ganesh Polychem Limited from April 1, 2025, and the application of equity method of accounting. A recognition of fair value movement on a long-dated USD forward contract impacted reported profitability.
Recent investments include the Greenfield Capex at Atali Project (Gujarat) with an estimated investment of ₹400 crore, aiming for approximately 80% capacity operationalization by Q4FY26, focusing on intermediates and CDMO/CMO services. Brownfield Capex at Tarapur (Maharashtra) involves an investment of ₹210 crore for an additional 9,000 MTPA capacity for Xanthine Derivatives, expected to be operationalized in Q1FY27.
Looking ahead, Aarti Pharmalabs expects CAPEX to be around ₹400 crore for FY27 and plans to initiate R&D investment in FY27 towards TIDES (Peptides & Oligonucleotides). The company is targeting a 15-18% Revenue and EBITDA CAGR over the next 3-4 years.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.